Researchers from the University of Sassari (Italy) and their collaborators have recently published findings from their research focused on the impact of one allelic variant in the CCND3 gene, encoding cyclin D3, on blood cell traits and resistance to malaria.
At a time of global transition for life sciences, with China stepping up the pace of innovation and the U.S. adopting protectionist policies, the health innovation region in Catalonia, Spain, is emerging as one of the most dynamic hubs in Europe. Last year, the region, centered on Barcelona, saw growth of 8.3% over 2024, and there are now 1,650 companies, including 423 biotechs, 259 digital health specialists and 238 med techs.
Beijing Konruns Pharmaceutical Co. Ltd. has patented new transforming acidic coiled-coil-containing protein (TACC) inhibitors described as potentially useful for the treatment of cancer.
Hangzhou Innogate Pharma Co. Ltd. has reported cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors. They are described as useful for the treatment of Aicardi-Goutieres syndrome, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, myasthenia gravis, multiple sclerosis, myocardial infarction and Parkinson’s disease, among others.
Chong Kun Dang Pharmaceutical Corp. has synthesized poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors designed for use in the treatment of cancer and inflammatory disorders.
Chugai Pharmaceutical has reported a new humanized antibody (Ab, SOF-10) that targets latent TGF-β1 and selectively blocks protease- and integrin αVβ8-mediated latent TGF-β1 activation.
The potential of G9A as a therapeutic target was investigated in vitro in vascular smooth muscle cells as well as in vivo in a murine model of vascular intimal hyperplasia.
Researchers from Shandong First Medical University (China) and collaborators have published a comprehensive study on the screening, synthesis, structure-activity relationship and biological evaluation of 1,2,4-oxadiazole derivatives that selectively inhibit SPHK2.
RSS
